trending Market Intelligence /marketintelligence/en/news-insights/trending/gypSZ6R7YtkRt9-vRY9OlQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Acasti notes unusual placebo response in failed phase 3 heart drug trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Acasti notes unusual placebo response in failed phase 3 heart drug trial

Acasti Pharma Inc.'s cardiovascular drug CaPre did not reduce triglycerides in patients with a chronic metabolic condition that heightens the risk of pancreatic and heart diseases, failing a phase 3 clinical trial.

CaPre was tested in patients with hypertriglyceridemia, which is characterized by high levels of triglycerides, a fat found in the blood. Patients with the condition have an elevated risk of developing pancreatic and heart diseases.

In the phase 3 trial called Trilogy 1, CaPre reduced triglyceride levels by 30.5% on average, compared to a 27.5% reduction seen in patients taking placebo at 12 weeks. Patients who received CaPre in addition to standard cholesterol therapy experienced an average triglyceride reduction of 42.2%, compared to a 31.5% reduction in patients in the placebo group. Acasti also reported a 36.7% average reduction in triglyceride levels for patients in the CaPre group at 26 weeks, compared to a 28% reduction in the placebo arm.

The Laval, Quebec-based pharmaceutical company said that Trilogy 1 did not achieve statistical significance due to an unexpectedly large percentage of patients who responded in the placebo group. CaPre's safety profile was similar to placebo as well. The company expects to report detailed results of the study by the end of the first quarter.

Simple cornstarch was used as a placebo in the study, surprising the company with a high response rate. Previous studies using corn oil, olive oil and vegetable oil as placebo experienced a maximum of 16% response in patients. Acasti is investigating the root cause of the significant placebo response as cornstarch is not likely the reason behind it.

Acasti said results from the ongoing Trilogy 2 study, which are expected in mid-February, may also provide useful data and a possible path forward to file an application with regulatory bodies for CaPre's approval.

Shares of Acasti plummeted as the U.S. markets opened Jan. 13, dropping more than 68% to 69 cents as of 11:25 a.m. ET. The shares previously closed at $2.25.